Materialise today announced that it has entered into a partnership with Exactech in order to offer 3D-printed implants for shoulder problems.
Materialise, a 3D printing and planning company based in Leuven (Belgium), offers medical applications 3D planning and printing services. Exactech, based in Gainesville Florida, develops innovative implants and instrumentation, as well as smart technologies, for joint replacement surgery.
They plan to work together to include the Materialise Glenius solution into the Exactech portfolio. This would enable surgeons in Europe and Australia to offer personalized implants.
Materialize announced in a press release that orthopedic surgeons can use its customized implants to treat patients suffering from significant glenoid bone damage. These patients do not receive long-term results with standard or augmented reverse shoulder implant.
“By including the Materialise Glenius implant into our existing offering, we’re providing surgeons in Europe and Australia access to an even more extensive shoulder portfolio,” said Chris Roche, Exactech SVP, extremities. “We are happy to partner with Materialise to bring greater personalization and additional artificial intelligence technology to shoulder reconstruction.”
Materialise’s engineers design each Glenius implant based on the patient’s unique anatomy. Materialise uses 3D data, simulation, and artificial intelligence (AI) to design each Glenius implant. Materialize stated that it strives to achieve more predictable outcomes in even the most difficult eroded-glenoid situations. Materialize optimizes the stability and fixation of the implant to maximize bone preservation.
“Demand is growing in the orthopedic industry for personalization of medical devices,” said Brigitte de Vet, VP, medical at Materialise. “Medical device companies adopt mass personalization by starting with high-value use cases and moving towards more high-volume applications. Materialise is dedicated to enabling researchers, engineers, and clinicians to revolutionize patient-specific treatment that improves clinical outcomes.”
0
0
